vs
Side-by-side financial comparison of DIVERSIFIED HEALTHCARE TRUST (DHC) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $379.6M, roughly 1.6× DIVERSIFIED HEALTHCARE TRUST). DIVERSIFIED HEALTHCARE TRUST runs the higher net margin — -5.6% vs -14.8%, a 9.2% gap on every dollar of revenue. On growth, DIVERSIFIED HEALTHCARE TRUST posted the faster year-over-year revenue change (-0.0% vs -10.5%). Over the past eight quarters, DIVERSIFIED HEALTHCARE TRUST's revenue compounded faster (1.2% CAGR vs -6.6%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
DHC vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $379.6M | $619.8M |
| Net Profit | $-21.2M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | -12.6% | — |
| Net Margin | -5.6% | -14.8% |
| Revenue YoY | -0.0% | -10.5% |
| Net Profit YoY | 75.7% | — |
| EPS (diluted) | $-0.09 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $379.6M | — | ||
| Q3 25 | $388.7M | $699.9M | ||
| Q2 25 | $382.7M | $613.9M | ||
| Q1 25 | $386.9M | $692.8M | ||
| Q4 24 | $379.6M | $707.8M | ||
| Q3 24 | $373.6M | $727.1M | ||
| Q2 24 | $371.4M | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $-21.2M | — | ||
| Q3 25 | $-164.0M | $-733.0M | ||
| Q2 25 | $-91.6M | $-255.4M | ||
| Q1 25 | $-9.0M | $-12.7M | ||
| Q4 24 | $-87.4M | $-178.4M | ||
| Q3 24 | $-98.7M | $-19.9M | ||
| Q2 24 | $-97.9M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | -12.6% | — | ||
| Q3 25 | -43.4% | -100.7% | ||
| Q2 25 | -24.5% | -29.4% | ||
| Q1 25 | -2.7% | 4.7% | ||
| Q4 24 | -26.1% | -14.2% | ||
| Q3 24 | -26.5% | 2.1% | ||
| Q2 24 | -23.0% | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | -5.6% | — | ||
| Q3 25 | -42.2% | -104.7% | ||
| Q2 25 | -23.9% | -41.6% | ||
| Q1 25 | -2.3% | -1.8% | ||
| Q4 24 | -23.0% | -25.2% | ||
| Q3 24 | -26.4% | -2.7% | ||
| Q2 24 | -26.3% | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.68 | $-10.78 | ||
| Q2 25 | $-0.38 | $-3.77 | ||
| Q1 25 | $-0.04 | $-0.19 | ||
| Q4 24 | $-0.37 | $-2.54 | ||
| Q3 24 | $-0.41 | $-0.30 | ||
| Q2 24 | $-0.41 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.4M | $140.4M |
| Total DebtLower is stronger | $2.4B | $2.5B |
| Stockholders' EquityBook value | $1.7B | $1.9B |
| Total Assets | $4.4B | $5.6B |
| Debt / EquityLower = less leverage | 1.47× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $105.4M | — | ||
| Q3 25 | $201.4M | $98.1M | ||
| Q2 25 | $141.8M | $151.7M | ||
| Q1 25 | $302.6M | $127.1M | ||
| Q4 24 | $144.6M | $98.3M | ||
| Q3 24 | $256.5M | $143.7M | ||
| Q2 24 | $265.6M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | $3.1B | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $2.0B | ||
| Q2 25 | $1.9B | $2.8B | ||
| Q1 25 | $1.9B | $3.0B | ||
| Q4 24 | $2.0B | $3.0B | ||
| Q3 24 | $2.0B | $3.2B | ||
| Q2 24 | $2.1B | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $4.4B | — | ||
| Q3 25 | $4.7B | $5.7B | ||
| Q2 25 | $4.8B | $6.4B | ||
| Q1 25 | $5.0B | $6.5B | ||
| Q4 24 | $5.1B | $6.4B | ||
| Q3 24 | $5.3B | $6.8B | ||
| Q2 24 | $5.3B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | 1.56× | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.6M | — |
| Free Cash FlowOCF − Capex | $-166.4M | — |
| FCF MarginFCF / Revenue | -43.8% | — |
| Capex IntensityCapex / Revenue | 38.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-280.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-19.6M | — | ||
| Q3 25 | $-49.3M | $-45.5M | ||
| Q2 25 | $53.0M | $-46.8M | ||
| Q1 25 | $-3.2M | $65.6M | ||
| Q4 24 | $112.2M | $63.7M | ||
| Q3 24 | $21.1M | $117.9M | ||
| Q2 24 | $44.3M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-166.4M | — | ||
| Q3 25 | $-89.8M | $-94.7M | ||
| Q2 25 | $18.8M | $-84.3M | ||
| Q1 25 | $-42.9M | $9.4M | ||
| Q4 24 | $-89.5M | $16.5M | ||
| Q3 24 | $-26.1M | $71.4M | ||
| Q2 24 | $3.3M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | -43.8% | — | ||
| Q3 25 | -23.1% | -13.5% | ||
| Q2 25 | 4.9% | -13.7% | ||
| Q1 25 | -11.1% | 1.4% | ||
| Q4 24 | -23.6% | 2.3% | ||
| Q3 24 | -7.0% | 9.8% | ||
| Q2 24 | 0.9% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 38.7% | — | ||
| Q3 25 | 10.4% | 7.0% | ||
| Q2 25 | 8.9% | 6.1% | ||
| Q1 25 | 10.2% | 8.1% | ||
| Q4 24 | 53.1% | 6.7% | ||
| Q3 24 | 12.6% | 6.4% | ||
| Q2 24 | 11.0% | 5.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DHC
| Senior Housing Operating Portfolio Segment | $323.4M | 85% |
| Rental Income | $56.2M | 15% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
